Olema Pharmaceuticals (OLMA) Other financing activities (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Other financing activities of $8.4 million for Q1 2026, up 3472.03% year-over-year from $236000.0 in Q1 2025, and up 6.98% quarter-over-quarter from $7.9 million in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Other financing activities (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Other financing activities for 7 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 3472.03% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $16.6 million (down 93.17% YoY), while the FY2025 annual figure was $8.4 million, down 96.55% from the prior year.
- Other financing activities rose to $8.4 million in Q1 2026 per OLMA's latest filing, from $7.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $242.4 million in Q4 2024 and bottomed at $7000.0 in Q2 2022.
- Historically, Other financing activities has averaged $24.4 million across 5 years, with a median of $235000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other financing activities soared 18928.57% — and 2025, when it slumped 96.75%.
- Olema Pharmaceuticals' Other financing activities stood at $106000.0 in 2022, then jumped by 120008.49% to $127.3 million in 2023, then soared by 90.41% to $242.4 million in 2024, then plunged by 96.75% to $7.9 million in 2025, then rose by 6.98% to $8.4 million in 2026.
- Business Quant data shows OLMA's Other financing activities at $8.4 million in Q1 2026, $7.9 million in Q4 2025, and $41000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.19 Mn |
| Mar 31, 2026 | 8.43 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 234,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Dec 31, 2024 | 242.42 Mn |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 920,000.00 |
| Dec 31, 2023 | -24,000.00 |
| Sep 30, 2023 | 128.21 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 220,000.00 |
| Sep 30, 2022 | 106,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 483,000.00 |
| Sep 30, 2021 | 57,000.00 |
| Dec 31, 2020 | 219.91 Mn |